Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John K Buolamwini

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Bioorganic & Medicinal Chemistry Letters|December 19, 2008
CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1)Amol Gupte, John K Buolamwini
Journal of Medicinal Chemistry|July 20, 2007
Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitorsWenwei Lin, John K Buolamwini
Medicinal Research Reviews|June 22, 2006
Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and developmentShantaram Kamath, John K Buolamwini
Journal of Medicinal Chemistry|October 17, 2003
Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitorsShantaram Kamath, John K Buolamwini
Journal of Medicinal Chemistry|February 8, 2002
CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active siteJohn K Buolamwini, Haregewein Assefa
Experimental Hematology & Oncology|August 24, 2019
A novel RNA variant of human concentrative nucleoside transporter 1 (hCNT1) that is a potential cancer biomarkerChunmei Wang, John K Buolamwini
Bioconjugate Chemistry|May 5, 2011
Design, synthesis, and evaluation of 2-diethanolamino-4,8-diheptamethyleneimino-2-(N-aminoethyl-N-ethanolamino)-6-(N,N-diethanolamino)pyrimido[5,4-d]pyrimidine-fluorescein conjugate (8MDP-fluor), as a novel equilibrative nucleoside transporter probeWenwei Lin, John K Buolamwini
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Novel halogenated nitrobenzylthioinosine analogs as es nucleoside transporter inhibitorsAmol Gupte, John K Buolamwini
Bioorganic & Medicinal Chemistry|September 21, 2007
Novel C2-purine position analogs of nitrobenzylmercaptopurine riboside as human equilibrative nucleoside transporter 1 inhibitorsAmol Gupte, John K Buolamwini
Bioorganic & Medicinal Chemistry Letters|December 23, 2008
Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitorsAmol Gupte, John K Buolamwini
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|December 19, 2008
CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1)Amol Gupte, John K Buolamwini
Journal of Medicinal Chemistry|July 20, 2007
Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitorsWenwei Lin, John K Buolamwini
Medicinal Research Reviews|June 22, 2006
Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and developmentShantaram Kamath, John K Buolamwini
Journal of Medicinal Chemistry|October 17, 2003
Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitorsShantaram Kamath, John K Buolamwini
Journal of Medicinal Chemistry|February 8, 2002
CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active siteJohn K Buolamwini, Haregewein Assefa
Experimental Hematology & Oncology|August 24, 2019
A novel RNA variant of human concentrative nucleoside transporter 1 (hCNT1) that is a potential cancer biomarkerChunmei Wang, John K Buolamwini
Bioconjugate Chemistry|May 5, 2011
Design, synthesis, and evaluation of 2-diethanolamino-4,8-diheptamethyleneimino-2-(N-aminoethyl-N-ethanolamino)-6-(N,N-diethanolamino)pyrimido[5,4-d]pyrimidine-fluorescein conjugate (8MDP-fluor), as a novel equilibrative nucleoside transporter probeWenwei Lin, John K Buolamwini
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Novel halogenated nitrobenzylthioinosine analogs as es nucleoside transporter inhibitorsAmol Gupte, John K Buolamwini
Bioorganic & Medicinal Chemistry|September 21, 2007
Novel C2-purine position analogs of nitrobenzylmercaptopurine riboside as human equilibrative nucleoside transporter 1 inhibitorsAmol Gupte, John K Buolamwini
Bioorganic & Medicinal Chemistry Letters|December 23, 2008
Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitorsAmol Gupte, John K Buolamwini
Pageof 5